DL-TBOA is a potent, non-transportable inhibitor of excitatory amino acid transporters (EAATs), with IC50 values of 70 μM, 6 μM, and 6 μM for EAAT1, EAAT2, and EAAT3, respectively, and Ki values of 42 μM (human EAAT1), 5.7 μM (human EAAT2), 4.4 μM (EAAT4), and 3.2 μM (EAAT5); it competitively blocks EAAT4 and EAAT5; in vitro, DL-TBOA enhances SN38-induced loss of cell viability and reverses oxaliplatin-induced loss of viability in HCT116 and LoVo cell lines, and decreases p53 induction by SN38 and oxaliplatin; in vivo, intracerebroventricular administration of DL-TBOA in morphine-dependent rats dose-dependently facilitates naloxone-precipitated somatic withdrawal signs and conditioned place aversion.